PB 62 of 2025
National Health (Originator Brand) Amendment Determination (No. 4) 2025
I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following Determination.
Dated 29 May 2025
REBECCA RICHARDSON
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments
National Health (Originator Brand) Determination 2015 (PB 100 of 2015)
This instrument is the National Health (Originator Brand) Amendment Determination (No. 4) 2025.
This instrument may also be cited as PB 62 of 2025.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 June 2025 |
|
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99ADB(6B) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Schedule 1, (after table item 61)
Insert:
Dienogest | Visanne |
|
|
2 Schedule 1, (after table item 176)
Repeal:
177 | Oxycodone | Endone OxyNorm OxyContin | Oral |
|
|
| Proladone | Rectal |
|
177A | Paclitaxel, nanoparticle albumin-bound | Abraxane |
|
|
177B | Palonosetron | Aloxi |
|
|
Substitute:
177 | Oxycodone | Endone OxyNorm OxyContin | Oral |
|
|
| Proladone | Rectal |
|
177A | Oxycodone with naloxone | Targin 2.5/1.25 mg Targin 5/2.5mg Targin 10/5mg Targin 15/7.5mg Targin 20/10mg Targin 30/15 mg Targin 40/20mg Targin 60/30 Targin 80/40 |
|
|
177B | Paclitaxel, nanoparticle albumin-bound | Abraxane |
|
|
177C | Palonosetron | Aloxi |
|
|
3 Schedule 1, (after table item 198)
Repeal:
199 | Ranitidine | Zantac |
|
|
Substitute:
199 | Ranitidine | Zantac Zantac 150 Zantac 300 |
|
|